Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 6
2018 4
2019 2
2020 2
2021 2
2022 3
2023 1
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ. Hutchings M, et al. Among authors: dimier n. J Clin Oncol. 2021 Jun 20;39(18):1959-1970. doi: 10.1200/JCO.20.03175. Epub 2021 Mar 19. J Clin Oncol. 2021. PMID: 33739857 Free PMC article. Clinical Trial.
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Sehn LH, et al. Among authors: dimier n. Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23. Lancet Oncol. 2016. PMID: 27345636 Clinical Trial.
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials.
Shi Q, Paiva B, Pederson LD, Dimier N, Talpes E, Prior TJ, Orfao A, Moreau P, Sonneveld P, Kumar SK, Dixon JG, Patel R, Bartlett BJ, Schecter J, McCarthy P, Hose D, Seckinger A, Mattia D, Goldschmidt H, Oliva S, Owen RG, Anderson KC, San-Miguel J, Durie BGM, Munshi N; International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM) Group. Shi Q, et al. Among authors: dimier n. J Clin Oncol. 2025 Apr 10;43(11):1289-1301. doi: 10.1200/JCO-24-02020. Epub 2025 Feb 12. J Clin Oncol. 2025. PMID: 39938021
Tumor flare with T-cell-engaging bispecific antibodies.
Carlo-Stella C, Dickinson MJ, Iacoboni G, Carpio C, Dimier N, Weisser M, Kwan A, Ferlini C. Carlo-Stella C, et al. Among authors: dimier n. Leuk Lymphoma. 2024 Oct;65(10):1524-1527. doi: 10.1080/10428194.2024.2361100. Epub 2024 Jun 5. Leuk Lymphoma. 2024. PMID: 38836333 No abstract available.
Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium.
Boyiadzis M, Wei AH, Paiva B, Freeman SD, Kaspers G, Chyla B, Hersey S, Patel R, Maloney B, Blanchet Zumofen MH, Van Hoef M, Wulff B, Obourn V, Patel S, Lopes de Menezes D, Shi Q, Bengoudifa BR, Dimier N, Prior TJ, Roboz GJ, Prebet T. Boyiadzis M, et al. Among authors: dimier n. Cancer. 2025 Jul 1;131(13):e35960. doi: 10.1002/cncr.35960. Cancer. 2025. PMID: 40576165 Free PMC article. Review.
Home care organization impacts patient management and survival in ALS.
Lavernhe S, Antoine JC, Court-Fortune I, Dimier N, Costes F, Lacour A, Camdessanché JP. Lavernhe S, et al. Among authors: dimier n. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):562-568. doi: 10.1080/21678421.2017.1332076. Epub 2017 Jun 6. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 28585472
Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials.
Dixon JG, Çağlayan Ç, Chihara D, Nielsen T, Dimier N, Zheng J, Wall AK, Salles G, Morschhauser F, Marcus R, Herold M, Kimby E, Blum KA, Ghielmini M, Shi Q, Flowers CR. Dixon JG, et al. Among authors: dimier n. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):e1009-e1018. doi: 10.1016/j.clml.2022.07.015. Epub 2022 Aug 3. Clin Lymphoma Myeloma Leuk. 2022. PMID: 36045021 Free PMC article. Clinical Trial.
21 results